Skip to main content
Triangle logo TriangleGet started

BMS-986504 (NCT06855771)

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9): a one-minute explainerNCT068557711 min

BMS-986504 trial for Carcinoma, Non-Small-Cell Lung (NCT06855771). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced or metastatic non-small-cell lung cancer that progressed after treatment and has deletion of both MTAP gene copies.

The idea: test navlimetostat, which blocks PRMT5 activity linked to cancer-cell growth. Randomized groups receive different doses, alone or with izalontamab brengitecan, an antibody-linked drug targeting EGFR and HER3. Researchers measure responses and side effects. Doses and schedules are not published.

This phase 2 study plans 182 patients. Bristol-Myers Squibb sponsors it; nine US sites are recruiting, including Boston.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.